Model‐based frequency‐and‐phase correction of 1 H MRS data with 2D linear‐combination modeling
Magnetic Resonance in Medicine · 2024
DOI: 10.1002/mrm.30209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance in Medicine, 2024. Verfasst von Dunja Simicic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Algorithms, Signal-To-Noise Ratio, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NIA NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Purpose
Retrospective frequency‐and‐phase correction (FPC) methods attempt to remove frequency‐and‐phase variations between transients to improve the quality of the averaged MR spectrum. However, traditional FPC methods like spectral registration struggle at low SNR. Here, we propose a method that directly integrates FPC into a 2D linear‐combination model (2D‐LCM) of individual transients (“model‐based FPC”). We investigated how model‐based FPC performs compared to the traditional approach, i.e., spectral registration followed by 1D‐LCM in estimating frequency‐and‐phase drifts and, consequentially, metabolite level estimates.
Methods
We created synthetic in‐vivo‐like 64‐transient short‐TE sLASER datasets with 100 noise realizations at 5 SNR levels and added randomly sampled frequency and phase variations. We then used this synthetic dataset to compare the performance of 2D‐LCM with the traditional approach (spectral registration, averaging, then 1D‐LCM). Outcome measures were the frequency/phase/amplitude errors, the SD of those ground‐truth errors, and amplitude Cramér Rao lower bounds (CRLBs). We further tested the proposed method on publicly available in‐vivo short‐TE PRESS data.
Results
2D‐LCM estimates (and accounts for) frequency‐and‐phase variations directly from uncorrected data with equivalent or better fidelity than the conventional approach. Furthermore, 2D‐LCM metabolite amplitude estimates were at least as accurate, precise, and certain as the conventionally derived estimates. 2D‐LCM estimation of FPC and amplitudes performed substantially better at low‐to‐very‐low SNR.
Conclusion
Model‐based FPC with 2D linear‐combination modeling is feasible and has great potential to improve metabolite level estimation for conventional and dynamic MRS data, especially for low‐SNR conditions, for example, long TEs or strong diffusion weighting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
ORCID-Profile: Dunja Simicic, Helge J Zöllner, Christopher W Davies-Jenkins, Kathleen E Hupfeld, Richard A E Edden, Georg Oeltzschner
Förderung
- NIBIB NIH HHS
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Simicic, D., Zöllner, H. J., Davies-Jenkins, C. W., Hupfeld, K. E., Edden, R. A. E., & Oeltzschner, G. (2024). Model‐based frequency‐and‐phase correction of 1 H MRS data with 2D linear‐combination modeling. Magnetic Resonance in Medicine. https://doi.org/10.1002/mrm.30209
Vancouver
Simicic D, Zöllner HJ, Davies-Jenkins CW, Hupfeld KE, Edden RAE, Oeltzschner G. Model‐based frequency‐and‐phase correction of 1 H MRS data with 2D linear‐combination modeling. Magnetic Resonance in Medicine. 2024. doi:10.1002/mrm.30209
BibTeX
@article{Simicic2024,
author = {Simicic, Dunja and Zöllner, Helge J and Davies-Jenkins, Christopher W and Hupfeld, Kathleen E and Edden, Richard A E and Oeltzschner, Georg},
title = {Model‐based frequency‐and‐phase correction of 1 H MRS data with 2D linear‐combination modeling},
journal = {Magnetic Resonance in Medicine},
year = {2024},
doi = {10.1002/mrm.30209}
}
EUVIMED